IDXG insider filings
INTERPACE BIOSCIENCES, INC. — 19 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen IDXG transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for IDXG between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — INTERPACE BIOSCIENCES, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Burnell Thomas W. — CEO, President & Chairman, Director | Option exercise (M): 1,966,763 @ $0 · Tax withholding (F): 581,718 @ $1.61 · Grant/award (A): 1,966,763 (derivative) @ $0 · Option exercise (M): 1,966,763 (derivative) @ $0 · Grant/award (A): 554,018 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | AGGARWAL VIJAY — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | KEEGAN JOSEPH D — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Rocca Fortunato R. — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | McCarthy Christopher — CFO & COO | Option exercise (M): 277,009 @ $0 · Grant/award (A): 554,018 (derivative) @ $0 · Option exercise (M): 277,009 (derivative) @ $0 · Grant/award (A): 277,009 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | SULLIVAN STEPHEN J — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | 1315 Capital II, L.P. — 10% owner | Conversion (C): 9,405,941 @ $2.02 · Conversion (C): 19,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Ampersand 2018 Limited Partnership — 10% owner | Conversion (C): 13,861,386 @ $2.02 · Conversion (C): 28,000 (derivative) @ $0 | EDGAR |
| 2025-04-25 | 4 | McCarthy Christopher — Chief Financial Officer | Option exercise (M): 7,556 @ $0 · Option exercise (M): 1,095 @ $0 · Option exercise (M): 7,556 @ $0 · Option exercise (M): 6,045 @ $0 · Option exercise (M): 15,112 @ $0 · Option exercise (M): 1,111 @ $0 | EDGAR |
| 2024-10-15 | 4 | 1315 Capital II, L.P. — 10% owner | Disposition to issuer (D): 19,000 (derivative) · Grant/award (A): 19,000 (derivative) | EDGAR |
| 2024-10-15 | 4 | Ampersand 2018 Limited Partnership — 10% owner | Disposition to issuer (D): 28,000 (derivative) · Grant/award (A): 28,000 (derivative) | EDGAR |
| 2024-02-06 | 4 | McCarthy Christopher — Chief Financial Officer | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2023-08-01 | 4 | McCarthy Christopher — Chief Financial Officer | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2022-02-02 | 4 | AGGARWAL VIJAY — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2021-05-25 | 4 | Burnell Thomas W. — President & CEO, Director | Purchase (P): 10,855 @ $8.68 | EDGAR |
| 2021-03-01 | 4 | Kamin Peter — 10% owner | Purchase (P): 14,946 @ $3.17 · Purchase (P): 16,360 @ $3.08 · Purchase (P): 14,874 @ $3.17 · Purchase (P): 14,726 @ $3.08 · Purchase (P): 8,333 @ $3.17 · Purchase (P): 8,252 @ $3.08 · +2 more | EDGAR |
| 2021-02-02 | 4 | Gorman Robert J. — Director | Grant/award (A): 12,438 @ $4.02 | EDGAR |
| 2020-12-02 | 4 | STOVER JACK E | Grant/award (A): 43,750 (derivative) @ $0 | EDGAR |
| 2020-12-02 | 4 | Burnell Thomas W. — President and CEO, Director | Grant/award (A): 100,000 @ $0 · Grant/award (A): 125,000 @ $0 | EDGAR |
Recent 8-K events — INTERPACE BIOSCIENCES, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-27 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-26 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-01 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — INTERPACE BIOSCIENCES, INC.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299123 (S-1) — latest: Amendment (S-1/A), filed 2026-10-30
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IDXG returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs